Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKFVX5)

• Drug Name: KUL-7211 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neurogenic bladder dysfunction	GC01.4	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 9798256
  TTD Drug ID: DMKFVX5

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor beta-3 (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mirabegron	DMS1GYT	Overactive bladder	GC50.0	Approved	[3]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[4]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[5]
Bopindolol	DMIFYLX	Hypertension	BA00-BA04	Approved	[6]
Mepindolol	DMUDWP9	Angina pectoris	BA40	Approved	[7]
Rimiterol	DMA47C6	Asthma	CA23	Approved	[8]
Bitolterol	DMK6XAV	Chronic obstructive pulmonary disease	CA22	Approved	[9]
Nipradilol	DMA65ER	Angina pectoris	BA40	Approved	[10]
Vibegron	DMFR201	Overactive bladder	GC50.0	Approved	[11]
ONO-2506	DMCA2PJ	Stroke	8B20	Phase 2/3	[12]

Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[13]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[14]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[15]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[16]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[17]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[18]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[19]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[20]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[21]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Modulator	[2]
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013676)
• [2] The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14.
• [3] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [4] Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
• [5] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [6] Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
• [7] Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
• [8] Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
• [9] Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
• [10] Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
• [13] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [14] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [15] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [16] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [17] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [18] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [19] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [20] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [21] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [22] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.